SPRY compared with MLYS: revenue, margins and what each company keeps, and the suppliers and customers both name

SPRYARS Pharmaceuticals, Inc.

Mkt capRevenueRevenue

MLYSMineralys Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

SPRYARS Pharmaceuticals, Inc.

MLYSMineralys Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SPRY

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±22.2%▼−7.38%×0.33

May 15 '26±11.3%▼−6.49%×0.58

Q1 FY26±22.8%▼−0.11%×0.00

Q3 FY25±18.0%▲+0.34%×0.02

MLYS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±9.5%▼−1.02%×0.11

May 7 '26±15.2%▼−2.56%×0.17

= impliedSPRY realized, solidMLYS realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±10.5%

▼−2.96%

×0.29

Q3 FY25±11.0%▲+5.87%×0.54

SPRYARS Pharmaceuticals, Inc.

2.62▼−14.10%· post 2.78· delayed

Mkt cap$266.4MRevenue$38MQ3 FY26Revenue$84MFY25

MLYSMineralys Therapeutics, Inc.

15.24▼−10.33%· post 15.24· delayed

After hoursNov 5 '26delayed

Mkt cap$1.5BRevenue—Revenue—

Compare

After hoursNov 5 '26delayed

SPRYARS Pharmaceuticals, Inc.

MLYSMineralys Therapeutics, Inc.

2.62▼−14.10%post 2.78delayed

Price

15.24▼−10.33%post 15.24delayed

$266.4M

Mkt cap

$1.5B

Q3 FY26$38M

Revenue

—

FY25$84M

Revenue

—

SPRY2.62▼−14.10%vsMLYS15.24▼−10.33%After hoursNov 5 '26delayed